Vital Signs - Drug Delivery: Current Challenges

 

Regular Price: USD 1,500

Special Price USD 1,050

30% OFF

* Required Fields

Regular Price: USD 1,500

Special Price USD 1,050

PAY BY INVOICE

Be the first to review this product

This issue of Vital Signs, released on August 25, 2008, provides an strategic overview of challenges relevant to drug delivery product design, valuation and commercial opportunity assessment for pharmaceutical & biotechnology companies. Additionally, a company spotlight is provided for Novocell, a stem cell engineering company dedicated to development, creation and commercialization of cell and drug based therapies for diabetes and other chronic diseases. Reimbursement and regulatory news from the FDA is also provided for the week of August 11, 2008.

Table of Contents

Vital Signs - Drug Delivery: Current ChallengesVital Signs: 25 August 2008This week's issue:




Keyword1

Keyword2

Keyword3

Related Research

Release Date : 07-Nov-17

Region : North America

Release Date : 06-Nov-17

Region : North America

Release Date : 31-Oct-17

Region : North America

Release Date : 30-Oct-17

Region : North America

Release Date : 25-Oct-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.